Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-human phase I trial of ADXS 11001 in patients with advanced, metastatic cervical cancer who have failed first line therapy.

Next Previous
X
Search
Trial Profile

A first-in-human phase I trial of ADXS 11001 in patients with advanced, metastatic cervical cancer who have failed first line therapy.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jul 2010

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axalimogene filolisbac (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Advaxis

    • Most Recent Events

    • 29 Jul 2010 Ongoing follow-up of surviving patients has shown that the patients who were alive in March are still alive, 3.5 and 3.9 years after initial dosing, according to an Advaxis media release.
    • 23 Mar 2010 Ongoing follow up of surviving patients has shown that two of 15 treated patients are still alive 1,248 and 1,128 days after initial dosing, according to an Advaxis media release.
    • 29 Dec 2009 Updated survival results reported in an Advaxis media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top